EnterNext welcomes Curetis on Euronext Amsterdam and Euronext Brussels


Curetis raises € 40 million, reaches market capitalization of € 151 million

Amsterdam, Brussels – 11 November 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs, today celebrated the listing of Curetis N.V. (the “Company” and, together with Curetis AG, “Curetis”), a developer of next-level molecular diagnostic solutions. Curetis listed on Euronext Amsterdam and Euronext Brussels (ticker code: CURE).

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions offered by Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in a few hours, a process that today can take up to days or even weeks with other techniques. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering countries across Europe, the Middle East and Asia.

The issue price of Curetis was set at € 10.00 per share. Market capitalization was € 151 million on the day of listing. The offering raised € 40 million altogether.

Oliver Schacht, CEO of Curetis said: “The IPO is a major milestone in Curetis´ corporate history and we are proud to join the group of renowned healthcare companies listed on Euronext. The proceeds of the transaction will mainly be used to expand the commercialization of our Unyvero Platform and to expand our product portfolio to address additional infectious diseases.”

Maurice van Tilburg, CEO of Euronext Amsterdam said: “We’re delighted to welcome Curetis today as part of its IPO and dual-listing on Euronext Amsterdam and Brussels. The dual-listing gives the company optimal visibility and exposure in both respective markets. The diversity of investors and combined liquidity in both markets offer Curetis strong access to capital which will help execute its strategy and support further development.”

Vincent van Dessel, CEO of Euronext Brussels: “We are happy to partner with Curetis as it enters in a new phase of its development. The company now benefits from strong financing solutions on Europe’s most active market for life sciences. The unique offering of multiple listing venues across our markets will help Curetis to create optimal conditions to enhance its visibility and liquidity as public traded stock.

Albert Ganyushin, Head of International Listings of Euronext added: “Curetis’ transaction is the second German company completing an IPO and the fourth international life sciences IPO on our markets recently and is a testament to the strength, resilience and growing international profile of our life science franchise. Including Curetis, Euronext has listed 15 IPOs of European life science companies since the start of 2015. We are delighted, especially considering the market volatility, that the potential of the diagnostic solutions developed and commercialized by Curetis has been recognized by the public market investors. This transaction demonstrates the capacity of Euronext markets to finance growth of European life science companies and the strength of our internationally established broker community focused on serving the European healthcare industry.”

To mark the listing, Curetis sounded the gong in Amsterdam to open the financial market.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.